News

Hosted on MSN4mon
Olix, Eli Lilly to develop liver disease drug under $630 million deal
Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly and Company to develop and commercialize treatments targeting cardiovascular and metabolic diseases. Olix will grant Eli ...
Yahoo Finance4mon
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
SEONGNAM, South Korea, February 10, 2025--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with ...
Business Insider4y
OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally
SUWON, Republic of Korea, Dec. 01, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that it recently completed a ...
Business Wire3y
OliX Announces Completion of USD 45 Million Capital Raise for R&D and Financial Structure Improvement
SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has successfully completed a capital raise to ...
Benzinga.com4mon
Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals
Lilly inks a global licensing deal with OliX for OLX75016, a Phase 1 candidate targeting MASH and other cardiometabolic conditions. Last Chance: See the "Power Pattern" That Delivered Winners 9 ...
Business Wire2y
OliX Pharmaceuticals Announces Positive Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar Treatment
SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive headline results of a phase 2a trial in the ...
Yahoo Finance3y
OliX Pharmaceuticals to Present at 2021 Oligonucleotide Therapeutics Society Virtual Conference
SUWON, Republic of Korea, Sept. 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company will present ...
GEN4y
OliX Advancing in Nucleic Acid Therapeutics
OliX Pharmaceuticals, a South Korean developer of RNAi therapeutics plans to expand its U.S. operations and advance up to 10 programs into clinical trials over the next three years—nearly ...
Nature1y
Developing RNAi therapeutics targeting hepatic and extra-hepatic diseases
Through its innovative asymmetric siRNA platforms, OliX Pharmaceuticals is opening up huge opportunities in RNA interference-therapeutic development to address unmet needs for various indications ...
Business Insider4y
OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars
Phase 2a trial follows the successful completion of OliX’s Phase 1 trial in the U.K. in November 2019 OliX retains global rights to develop and commercialize OLX10010 outside Asia SUWON ...
FiercePharma4y
OliX allies with PCI to develop dermatological RNAi therapies
OliX Pharmaceuticals and PCI Biotech have partnered to develop dermatological RNAi therapies. The collaborators will use PCI’s intracellular delivery platform to try to get nucleic acids inside ...